淋巴瘤 在华治疗
对于复发或难治性大B细胞淋巴瘤，中国有四款获批的CD19 CAR-T产品：axi-cel、relma-cel、瑞基奥仑赛和纳基奥仑赛。其中仅axi-cel同时获FDA批准。卡瑞利珠单抗在中国获批用于三线经典型霍奇金淋巴瘤。患者可通过医院血液科或临床试验获取治疗。
已核验最后核验
可用疗法
| 可用疗法 | 在华状态 | 在美状态 | 信息来源 |
|---|---|---|---|
| Axicabtagene ciloleucel (Yikaida / Yescarta), CD19 CAR-T | 在中国已获批 | 在中国已获批 | National Healthcare Security AdministrationElevar Therapeutics / GlobeNewswire |
| Relmacabtagene autoleucel (Carteyva), CD19 CAR-T | 在中国已获批 | 未获批 | PubMed CentralElevar Therapeutics / GlobeNewswire |
| Ranicabtagene autoleucel (HICARA), CD19 CAR-T | 在中国已获批 | 未获批 | JW TherapeuticsElevar Therapeutics / GlobeNewswire |
| Inaticabtagene autoleucel, CD19 CAR-T | 在中国已获批 | 未获批 | Elevar Therapeutics / GlobeNewswire |
| Camrelizumab (PD-1) for relapsed/refractory classic Hodgkin lymphoma, third line | 在中国已获批 | 未获批 | Shanghai Hengrun Dasheng (Harin Bio) |
有公开项目的医院
以下为有来源的公开信息，不构成推荐。
Shanghai上海交通大学医学院附属瑞金医院Ruijin Hospital, Shanghai Jiao Tong University School of MedicineInternational deptVerified
Shanghai复旦大学附属肿瘤医院Fudan University Shanghai Cancer CenterInternational deptReported
Beijing北京大学肿瘤医院Peking University Cancer Hospital (Beijing Cancer Hospital)No public intl deptVerified
Guangzhou中山大学肿瘤防治中心Sun Yat-sen University Cancer CenterInternational deptVerified
Hainan / Boao Lecheng上海交通大学医学院附属瑞金医院海南医院（海南博鳌研究型医院）Ruijin Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Boao Research Hospital)International deptReported
Chengdu四川省肿瘤医院Sichuan Cancer HospitalNo public intl deptVerified
Kunming云南省第一人民医院First People's Hospital of Yunnan ProvinceInternational deptVerified
Shenzhen中国医学科学院肿瘤医院深圳医院Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen CenterNo public intl deptVerified
临床试验
585项研究正在中国招募（ClinicalTrials.gov，截至 2026-10-26）. 查看列表
我们只提供试验链接；是否入组由试验团队决定。据 AFP 报道，自 2026 年 5 月起中国禁止向患者收取临床研究费用。
常见问题
中国有多少款治疗淋巴瘤的CAR-T产品？
2026年6月国家医保局文件列出四款用于复发或难治性大B细胞淋巴瘤的已上市CAR-T产品：阿基仑赛、瑞基奥仑赛、瑞基奥仑赛和纳基奥仑赛。瑞基奥仑赛还适用于滤泡性淋巴瘤。
[1] National Healthcare Security Administration[2] JW Therapeutics淋巴瘤CAR-T是否纳入中国国家医保？
截至2026年6月尚未纳入：国家医保局文件显示，这四款产品均未进入国家基本医疗保险药品目录。外国患者通常需自费。
[1] National Healthcare Security Administration信息来源
- 2026 National Reimbursement Drug List application: ranicabtagene autoleucel (public version)
“In r/r large B-cell lymphoma, four CAR-T products are marketed in China (axicabtagene, relmacabtagene, ranicabtagene, inaticabtagene), none yet in the national basic medical insurance drug list.”
- A New Outcomes-Based Payment Plan From a Chinese Company to Improve Patient Affordability of CAR-T Product
“Lists Yikaida (axicabtagene ciloleucel) at about 1.166 million yuan per infusion and inaticabtagene at about 0.999 million yuan.”
- NMPA acceptance of sBLA for Carteyva as second-line treatment in r/r LBCL
“Carteyva has been approved by NMPA for three indications.”
- Harin Bio's CD19 CAR-T HICARA (Ranicabtagene Autoleucel Injection) Approved for Marketing
“On July 30, 2025, the National Medical Products Administration formally approved the New Drug Application for Ranicabtagene Autoleucel Injection (HICARA).”
- Elevar Therapeutics Receives FDA Complete Response Letter for rivoceranib plus camrelizumab in HCC
“Camrelizumab is currently approved for eight indications in China, including relapsed/refractory classic Hodgkin's lymphoma (third-line) and esophageal squamous cell carcinoma.”
- 16 CAR-T Therapies and Counting
“Seven therapies have been approved by the U.S. FDA.”
本站仅提供信息，不构成医疗建议、诊断或治疗推荐。请咨询你的医生。紧急情况请立即拨打当地急救电话。